Liver transplantation in Wilson’s disease: Single center experience from Saudi Arabia

Table 1 Baseline characteristics of 16 Wilson’s disease patients’ pre-transplant details

Case	Age (yr)	Gender	Nationality	Ascites	Jaundice	HE	Neuro	24-h Copper	Ceruloplasmin	Penicillamine	KF ring	CTP	MELD
1	14	F	Saudi Arabia	Yes	Yes	No	Yes	-	100	Yes	Yes	C	19
2	14	F	Saudi Arabia	Yes	Yes	Yes	No	-	155	-	No	C	31
3	3	M	Saudi Arabia	No	Yes	No	No	-	325	Yes	No	B	12
4	12	M	Saudi Arabia	No	Yes	No	No	14.1	395	Yes	No	B	11
5	8	M	Saudi Arabia	Yes	Yes	No	No	-	250	-	No	B	11
6	4	M	Saudi Arabia	Yes	Yes	Yes	No	4.5	< 71	Yes	No	C	18
7	12	F	Saudi Arabia	No	Yes	No	No	10.02	54	Yes	No	B	10
8	38	M	Saudi Arabia	Yes	Yes	No	No	14	71	-	No	B	19
9	13	M	Saudi Arabia	Yes	Yes	No	No	10.2	227	Yes	No	B	13
10	6	M	Syrian Arab	Yes	Yes	No	No	-	< 72	-	No	B	13
11	25	F	Saudi Arabia	Yes	Yes	Yes	Yes	6.84	< 71	Yes	Yes	A	12
12	23	F	Saudi Arabia	Yes	Yes	Yes	Yes	0.89	128	-	Yes	C	34
13	18	M	Saudi Arabia	Yes	Yes	No	No	37	346	Yes	No	C	27
14	7	F	Saudi Arabia	No	Yes	No	No	17.06	360	Yes	No	A	-
15	22	F	Saudi Arabia	Yes	Yes	Yes	Yes	1.86	< 71	Yes	Yes	A	14
16	5	M	Yemeni	No	Yes	No	No	0.88	373	-	No	B	-

Age: Age at the time of diagnosis of Wilson’s disease; M: Male; F: Female; HE: Hepatic encephalopathy; KF ring: Kayser-Fleischer ring; CTP: Child-Turcotte-Pugh score; MELD: Model for end-stage liver disease; Penicillamine: These patients had received treatment with D-penicillamine prior to liver transplantation.